Medication evidence profile

Ergoloid Mesylates

Ask about Ergoloid Mesylates

Clinical overview

Ergoloid Mesylates has a public medication-list entry in KABS 2020 open validation supplement. This profile has one source version to examine, so a cross-scale comparison is not available from these rows.

Source-specific scores

SourceScore
JARSNot listed
Yamada-ABSNot listed
BAASNot listed
Swe-ABSNot listed
GABSNot listed
KABS0
CALSNot listed

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

How to interpret the evidence

1 of 7 public source versions contain an explicit medication-list entry for ergoloid mesylates.

KABS 2020 open validation supplement explicitly records zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 1 observation
  1. KABS 2019 scale - 2020 open validation supplement

    Source label: Ergoloid mesylates. Published value: 0.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Cardiovascular drugs; table row 58
    Observation: KABS2020_SUPP_0242; rating state: published_zero.

What this page does not establish

  • No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, Swe-ABS 2023, GABS 2018, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Ergoloid Mesylates

Ask about this medication